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Prolidase catalyzes the cleavage of dipeptides containing proline on their C
terminus. The reduction in prolidase activity is the cause of a rare disease
named ’Prolidase Deficiency’. Local structural disorder was indicated as one
of the causes for diminished prolidase activity. Previous studies showed that
heat shock proteins can partially recover prolidase activity in vivo. To ana-
lyze this mechanism of enzymatic activity rescue, we compared the crystal
structures of selected prolidase mutants expressed in the absence and in the
presence of chaperones. Our results confirm that protein chaperones facilitate
the formation of more ordered structures by their substrate protein. These
results also suggest that the protein expression system needs to be considered
as an important parameter in structural studies.
Databases
The reported crystal structures and their associated structure factor ampli-
tudes were deposited in the Protein Data Bank under the accession codes
6SRE, 6SRF, and 6SRG, respectively.
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Prolidase (PEPD, Xaa-Pro dipeptidase, ECnonbreak
ingspace3.4.13.9) is the only known enzyme in
humans capable of hydrolyzing dipeptides containing
an imino acid on their C terminus [1]. As a result,
free proline is produced, which can be salvaged for
reuse by the cell. This activity is of particular impor-
tance in collagen metabolism [2–4]. Decreased or
absent prolidase activity frequently leads to the
development of a syndrome referred to as prolidase
deficiency (PD), which is characterized by a broad
spectrum of clinical symptoms with the most com-
mon ones being chronic skin ulcerations, recurring
respiratory system infections, and mental retardation
[4–8]. PD is a rare recessive genetic disorder with
only a little over a hundred patients diagnosed to
date (www.orpha.net; ORPHA: 742). In PD patients,
35 mutations could be mapped to the PEPD gene
including 16 missense mutations and nine insertions/
deletions [9]. A series of eight mutations that result
in single amino acid deletion or substitution has
recently been analyzed by X-ray crystallography. In
three of the resulting crystal structures, namely in the
structures of the Ser202Phe, Gly287Asn, and
Gly448Arg variants of the enzyme, significant level
of protein disorder in the region winding around the
active site was observed [10].
Abbreviations
ADP, atomic displacement parameters; LOF, loss of function; PD, prolidase deficiency; wt, wild-type.
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The prevention or reversion of structural disorder as
a cure for a disease has been little studied, especially
at the molecular level. In spite of this, one could envi-
sion that a drug molecule, such as for instance a
shape-specific antibody, an aptamer or a small mole-
cule, has a stabilizing effect on the native structure. In
fact, such small molecular agents referred to as phar-
maceutical chaperones [11] have been investigated for
a number of targets related to protein misfolding
[12,13] resulting in several drug candidates and
approved drugs [14]. Yet, the development of such a
stabilizing agent is usually a tedious project [11–13,15]
and the utmost importance of structural biology was
underlined in such investigations [16].
Another possibility is to help the protein to fold
correctly from the very beginning, that is, during
translation, to assume a more stable structure. In
2013, Besio et al. [17] showed that the induction of
the expression of Hsp70 and Hsp90 in human fibrob-
lasts led to protein stabilization and partial recovery
of prolidase activity (up to 40% depending on the
mutant in question). Molecular chaperones are spe-
cialized proteins that assist cotranslational protein
folding. They also play a role in refolding of mis-
folded proteins and can help in dissolving protein
aggregates and target misfolded proteins for degrada-
tion [18]. Several approaches to modulate chaperone
activity were developed and investigated primarily in
neurodegenerative disorders [19,20], and the pharma-
cological induction of chaperone proteins was recently
shown to be a potent way of ameliorating amyloid-
like aggregation involving protein kinase Cc [21].
Chaperone co-expression is often also advantageous
for heterologous protein expression [22–24]. All these
effects of chaperones have their basis in the function-
ing of chaperones as folding catalysts, usually with a
rather broad substrate spectrum. However, to the
best of our knowledge, there is no study, which had
analyzed the impact of the presence or absence of
chaperones during protein expression on the 3D
structure of proteins.
In this study, following the report of Besio et al. as
well as our previous crystallographic studies, we ana-
lyzed the crystal structures and the activity profiles
of three selected, structurally disordered prolidase
variants co-expressed in the presence of chaperones,
and compared our findings to previous results based
on protein preparations from an expression back-
ground which is devoid of increased chaperone activ-
ity. We demonstrate a significant effect of the
chaperones on both the final protein structure and its
activity.
Materials and methods
Protein expression and purification
The three selected prolidase variants were expressed in
Escherichia coli Arctic Express (DE3) (Agilent, Waldbronn,
Germany) cells. The cells were transformed with a pET28a
plasmid bearing the prolidase gene with the desired muta-
tion. The cells were grown in TB at 37 °C. When the
OD600 value was about 1.0, the temperature was decreased
to 10 °C and protein expression was induced by the addi-
tion of IPTG to a final concentration of 0.5 mM. The cells
were left overnight and then harvested by centrifugation
and suspended in lysis buffer (50 mM Tris/HCl pH 7.8,
300 mM NaCl, 20 mM imidazole, 10% (v/v) glycerol,
10 mM b-ME). They were then disrupted by sonication
(15 min, 5-s pulse/3-s pause cycles), and the soluble frac-
tion was separated from cell debris by centrifugation
(45 min, 4 °C, 53 000 g) and loaded onto an equilibrated
5 mL HisTrap column (GE Healthcare Europe GmbH,
Freiburg, Germany). Unspecifically bound contaminants
were washed from the affinity column with buffer A
[50 mM Tris/HCl pH 7.8, 200 mM NaCl, 40 mM imidazole,
5% (v/v) glycerol, 5 mM b-ME] until no further signal
decrease was observable. Specifically bound protein was
eluted with buffer B [50 mM Tris/HCl pH 7.8, 200 mM
NaCl, 400 mM imidazole, 5% (v/v) glycerol, 5 mM b-ME]
and dialyzed against storage buffer (50 mM Tris/HCl pH
7.8, 200 mM NaCl, 5 mM b-ME). During dialysis, 2 mg of
TEV protease per 100 mg of prolidase was added. The dia-
lyzed protein was concentrated and subjected to size exclu-
sion chromatography using a Superdex 200 (16/600) pg
column (GE Healthcare Europe GmbH) equilibrated with
storage buffer. A single peak corresponding to prolidase
was collected, concentrated to ~ 50 mgmL1, and used for
crystallization trials or aliquoted and flash-frozen in liquid
nitrogen (LN2) for later use. Prolidase expression in
Rosetta (DE3) cells followed the same procedure and was
previously described [10,25].
Protein crystallization
Purified prolidase was crystallized as previously reported
[10,25]. Protein solution in storage buffer (13–18 mgmL1)
was set up in sitting drop 96-well Intelli low-profile crystal-
lization plates as a 1 : 1 mix with reservoir solution (10 mM
sodium tetraborate and 720–1050 mM sodium citrate, pH:
7.5–8.5). Well-shaped 3D protein crystals of ~ 100 µm in
the longest direction appeared after 3–6 days of incubation
at room temperature in most wells on the plate. The best
crystals were mounted using litholoops, cryopreserved in
1200 mM sodium citrate, 20% (v/v) glycerol, supplemented
with 20 mM MnCl2 and 20 mM GlyPro, and flash-cooled in
LN2.
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Diffraction data collection and structure solution
and refinement
X-ray diffraction data were collected at beamline BL14.1 of
the BESSY electron storage ring operated by the Helmholtz-
Zentrum Berlin. The data were recorded at 13.5 keV, which
is the critical energy of the beamline’s insertion device
[26,27]. The phase problem was solved by molecular replace-
ment using the program PHASER [28] and the wild-type (wt)
prolidase structure (PDB-ID 5M4J [25]) as a search model.
Optimal model placement in the asymmetric unit was verified
with the program ACHESYM [29]. In order to ensure repro-
ducibility, for each variant expressed from both expression
backgrounds several (≥ 5) crystals originating from different
crystallization drops were analyzed by X-ray diffraction.
Since no significant differences could be observed between
crystals from the same variant and the same expression back-
ground, only one model per variant and per expression back-
ground was subjected to full refinement and reported here.
Structures were submitted to several model rebuilding and
refinement cycles using COOT [30] and phenix.refine [31,32].
Refined models and reduced experimental data were depos-
ited in the Protein Data Bank (PDB) [33,34] under the acces-
sion codes 6SRE, 6SRF, and 6SRG. Relevant data collection
and refinement statistics are summarized in Table S1 for the
structures derived from Arctic Express cells. For the struc-
tures derived from Rosetta cells, the relevant parameters have
been reported previously [10,25].
Structure analysis and comparison
Structural analysis and comparisons were executed in COOT
[30] and PYMOL (The PyMOL Molecular Graphics System,
Version 2.0, Schr€odinger, LLC, New York, NY, USA),
and atomic displacement parameter (ADP) variabilities
were analyzed with the program Baverage from the CCP4
suite [35]. The CaRMSD for the regions of interest was
plotted in Figs 2–4, and the full list of numerical values is
reported as Table S2. Normalized B factor values were
obtained by dividing the local ADP by the average ADP
for the entire model using the values derived from Baver-
age. The phenix.ensemble_refinement [36] was run for each
analyzed model using the implementation in Phenix GUI
with default parameters and the deposited model as an
input. The residue average root mean square fluctuations
(RMSFs) for atom coordinates and ADPs in the final
ensemble model were calculated using ens_rmsf command
from PYMOL ens_tools plugin [37] and were plotted for the
region of interest.
Protein stability test
In order to investigate protein stability, the melting temper-
atures of all protein variants were determined by a thermal
shift assay (TSA). The experiment was performed as
described previously [38]. The protein solution (4 mgmL1)
was incubated with 1 : 500 diluted Sypro orange dye and
in an assay buffer (50 mM Tris, pH 8.0, 250 mM NaCl,
1 mM MnCl2). The fluorescence signal (kex = 492 nm,
kem = 610 nm) from Sypro orange was determined as a
function of temperature between 5 and 95 °C in increments
of 0.5 °Cmin1. The melting temperature was calculated as
the negative inflection point of the fluorescence curve. Each
experiment was performed in triplicate.
Prolidase activity assay
A prolidase activity assay was performed according to the
previously described method [39], but was adjusted to mea-
surements using a plate reader. In short, 50 µL of 10 µM of
the appropriate prolidase variant in 50 mM Tris, pH 8.0,
250 mM NaCl, and 1 mM MnCl2 buffer was incubated at
37 °C in the presence of 20 µL of 250 mM GlyPro. After
30 min, the reaction was stopped by the addition of
135 µL of 100% solution of TCA and 150 µL of Chinard’s
reagent. The mix was then incubated for 5 min at 95 °C.
Denatured protein samples were centrifuged for 5 min at
17 000 g, and 100 µL of each sample was transferred onto
a transparent 96-well plate and the absorbance at 515 nm
was measured. To make sure that no more than 5% of sub-
strate was consumed, the results were compared against a
calibration curve prepared by measuring the absorption
from increasing proline concentrations in 5 mM HCl-treated
alike protein samples. During data analysis, the values were
normalized to the activity of wt prolidase. Each experiment
was performed in triplicate.
Results
Wild-type hsProl—the reference
Wild-type human prolidase is a homodimer composed
of two subunits. Each monomer harbors two domains
with active sites located at the bottom of so-called pita-
bread fold, which is characterized by two highly bent b-
sheets flanked by four a-helices [40]. It forms a deep
cleft at the bottom of which two manganese ions are
bound. Upon substrate binding, the active site is sealed
from the top by a flexible helix from the opposing N-
terminal domain [25]. Figure 1 gives an overview of the
3D structure of prolidase. From the electron density
shown in the inset of Fig. 1, it is clearly evident that all
three mutation sites discussed in this work are com-
pletely ordered in the wt structure.
Ser202Phe—mild stabilization
The analysis of the Ser202Phe prolidase variant
expressed in Rosetta cells (Prol_S202F_Ros) shows
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that the introduction of the bulky, hydrophobic pheny-
lalanine side chain replacing a small serine pushes the
neighboring b-strand (encompassing residues 271–281)
which harbors two glycine residues (277–278). The
effect of this shift is amplified in the next strand (resi-
dues 237–248) where the electron density map becomes
discontinuous and main chain could not be traced
completely (Fig. S2). It can also be observed that the
ADP values are increased significantly for the entire
strand, including the two maxima around residues 240
and 260 (Figs 2C and S2). This region is also charac-
terized by highly elevated flexibility as indicated by
coordinate and B factor RMSF obtained from ensem-
ble refinement analysis. This part of the chain harbors
the residues Tyr241 and His256, which were previously
shown to play a role in the stabilization of the active
site and the transition state during catalysis. In the
structure obtained from the protein produced in Arctic
Express cells (Prol_S202F_ArEx), the ADP values are
also increased for one of the strands, but the increase
is not as strong as in the Prol_S202F_Ros case and
electron density remains continuous and well defined
even for the Arg side chains protruding over to the
opposite subunits (Fig. S2). Also, the flexibility is low-
ered and concentrated around two residues (240 and
260) rather than for the entire region (Fig. 2D,E). The
mutation caused a significant decrease in protein
stability expressed as TM, but no significant differences
in this regard were observed due to expression system
(Fig. 5A).
Gly278Asp—significant stabilization
Gly278 is located in one of the b-strands (271–281)
next to the active site of prolidase. The introduction of
an Asp side chain in this position disrupts the trace of
the neighboring strand (237–248), which leads to sig-
nificant disorder in the proximity of the active site of
the enzyme expressed in Rosetta cells (Prol_G278-
D_Ros). The loss of electron density details hampers
the chain tracing for part of this strand (Fig. S3). Con-
comitantly, the ADP values are increased for one of
the strands and part of the chain around 252–263 has
been displaced (Figs 3A,C, and S3). The large increase
in protein flexibility for these strands and loops con-
necting them is also evident from the RMSF plots
(Fig. 3D,E). For the structure of the protein produced
in Arctic Express (Prol_G278D_ArEx), much clearer
electron density can be observed, as well as lower
ADP values for some parts, such as for instance for
residue Leu274 or Arg237. Above all, the chain frag-
ments 252–263 become completely ordered and follow
the trace expected from the wt HsProl (Figs 3 and S3).
These differences are also reflected in the B normalized
Fig. 1. Structural overview of human prolidase. A C2-symmetric homodimer of prolidase is drawn with cartoon representation. In addition, a
semi-transparent surface representation is shown for monomer A. Monomer A is colored according to its domain organization with the N-
terminal domain in blue and the catalytic C-terminal domain in green. Monomer B is colored in light gray, while the pita-bread motif is
highlighted in red. Substrate molecules and metal ions are shown in black ball-and-stick representation. The stars indicate the relative
positions of the three discussed mutations. The enlargement shows a fragment of human prolidase shown in stick representation, which
forms part of the active site cavity and is directly affected by the discussed mutations. The mutation sites are indicated by residue names
and numbers, and the electron density map shown is a composite omit electron density map contoured at 1.0 r. The enlarged fragment is
colored blue (N-) to red (C-) following the chain trace to ease the localization of the described mutants. The substrate and metal ions are
drawn as black ball-and-stick representation to indicate the location of the active sites. The image was prepared based on the PDB entry
5M4J [24].
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plot (Fig. 3C). The coordinate and B factor fluctua-
tions remain elevated yet to much lesser extent than in
the Prol_G278D_Ros model. Interestingly, the point
of substitution differs significantly between two mod-
els. In the Prol_G278D_Ros model, the main chain
seems unaltered around Asp278 and the aspartate itself
displays elevated ADPs for side chain only. In con-
trast, in the Prol_G278D_ArEx model the entire
Asp278 and its neighboring residues display signifi-
cantly higher than average ADPs which are also
reflected as a sharp peak on the B normalized plot
(Figs 3C and S3). A striking difference is the confor-
mation of the introduced side chain. In the Rosetta
model, it is directed toward the neighboring strand,
while in Arctic Express one it is swung outwards at
the cost of an increase in the local ADP. Apparently,
this allows for a better overall preservation of the b-
sheet structure (Fig. 3A). Regardless of the expression
system, the TM of G278D variant is decreased with
respect to the wt protein (Fig. 5A).
Gly448Arg—no structural differences
The substitution of Gly448 by an Arg residue leads to
the displacement of a large portion of polypeptide
chain connecting two antiparallel b-strands forming
one side of the pita-bread fold. This is the largest dis-
order described for prolidase variants covering a dozen
residues and also affecting flexibility of active site resi-
dues (e.g., Tyr241 and crucial His255). Surprisingly, it
has relatively little effect on the overall protein stabil-
ity (Fig. 5A). In this case, no significant structure sta-
bilization was achieved by co-expression with
chaperonins as the crystal structure of protein
obtained from Arctic Express is virtually identical with
the one obtained from Rosetta cells (Fig. 4). Above
others, it maintains structural disorder manifested as
diffuse electron density, gaps in the model (Fig. S4),
and large increase in protein flexibility (Fig. 4D,E).
In vitro enzymatic activity
In order to estimate the effect of the chaperone on the
final structure and function of prolidase, the relative
enzymatic activities of all prolidase preparations
in vitro were analyzed. In the enzymatic assay, the
amount of proline released in a time unit was mea-
sured by a colorimetric reaction using Chinard’s
reagent. The result obtained for wt prolidase was
taken as the reference and defined as 100% (see the
Materials and methods section for more details). No
significant proline release was measured in neither of
the Ser202Phe preparations, showing that the
chaperone activity was not able to rescue the enzy-
matic function of the enzyme, despite its effect on the
3D structure. For the other two variants, a higher pro-
line release was measured for the prolidase prepara-
tions from Arctic Express compared with the
preparations from Rosetta cells (Fig. 5B). No signifi-
cant impact on the overall protein stability was
observed, and the reaction was conducted at least 8 °C
below TM of the least stable variant. This demon-
strates that the chaperone activity was able to partially
rescue the enzymatic activity of prolidase.
Discussion
Human prolidase plays an important role in proline
turnover. Despite PD being a rare disease with esti-
mated occurrence of 1–2 cases per million births, more
than 30 mutations were associated with PD, OMIM
170100 [17], and new ones are still being identified
(Natalia Duarte Linhares, personal communication).
Several studies showed the potential increase in total
prolidase activity in cultured fibroblasts [41–44] and
various therapeutic therapies were investigated [9,45–
51], but to date no efficient treatment was introduced.
In recent years, we have structurally characterized wt
prolidase [25] and a series of eight single amino acid
substitution or deletions [10] and we could show that
one of the major causes of loss of function (LOF) was
structural destabilization induced by bulky side chains
introduced in places of small ones. Previously, Besio
et al. showed that the induction of the chaperonins
Hsp90 and Hsp70 in cultured fibroblasts derived from
patients leads to partial rescue of prolidase activity.
The effect seems to be case-dependent and varies from
negligible to about 40% [17]. This could potentially
improve the patients’ well-being by for example chang-
ing disease manifestations from acute to mild. LOF
variants of proteins are generally little studied, and
their activation poses bigger challenge that inhibition
of a given activity. Nevertheless, several approaches
have been investigated with some success [16]. One of
the approaches was the development of so-called phar-
maceutical chaperones [12], but to the best of our
knowledge activation of natural protein chaperones as
a way of stabilizing LOF enzymes has not been widely
tested and such effect was never proved by means of
structural biology.
In this study, the aim was to investigate the effect of
co-expression of chaperones with several LOF proli-
dase variants. Our primary focus was on structure sta-
bilization. Since chaperones are known to facilitate
proper protein folding, we have selected three mutants
for which significant structural alterations could be
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identified. For the remaining ones, the stabilizing effect
observed by Besio et al. could not be linked to protein
structure. Also, the wt protein which was shown to be
active and fully folded was limited to the standard
expression protocol, since we did not expect any fur-
ther influence of the chaperone-rich expression back-
ground. The simplest system allowing us to obtain
protein expressed in the presence of chaperones in an
amount sufficient for crystallization was E. coli Arctic
Express strain. This strain constitutively expresses a
variant of cold-adapted chaperonins (Cpn10 and
Cpn60) from Oleispira antarctica [24,23], which are
homologues of E. coli GroEL/GroES. Similar to
human Hsp70/Hsp90, Cpn10 and Cpn60 can utilize a
broad spectrum of substrates and require ATP for the
activity. By using the E. coli expression system and
identical purification and crystallization protocols as
previously, we minimized the source of differences
between the analyzed crystal structures and we have
good reasons to believe that the presence of chaper-
ones during protein expression is the main source of
observed effects.
In all three analyzed structures, a small amino acid
side chain was replaced by a bigger, bulkier side chain
which led to the repulsion of a neighboring main chain
segment, ultimately leading to its disordering. This
effect was limited to a fragment encompassing two of
the active site-forming antiparallel b-strands (Arg237-
Glu248 and Met271-Tyr281) and the loop connecting
them, also containing elements forming the active site.
Interestingly, the Phe side chain in the Ser202Phe vari-
ant collides with the glycines 278 and 279, that is, with
Fig. 2. Comparison of the Ser202Phe
variant of prolidase derived from two
different expression systems with the wt
prolidase structure. (A) Superposition of
mutant models (Prol_S202F_Ros—yellow,
Prol_S202F_ArEx—green) with wt human
prolidase in light gray. The site of
substitution is highlighted in purple, and
the substrate is shown in black. The
discontinuity in the Prol_S202F_Ros model
comprising residues 241–243 is
approximated by a dashed line. (B)
Differences between Ca atoms (CaRMSD)
based on the superposition of the mutant
model with wt human prolidase. (C)
Variability of normalized B factors drawn
for discussed region in Prol_S202F
models. (D, E) RMSF of average residue
coordinates and ADPs, respectively, based
on the ensemble refinement. The coloring
scheme is the same as for the structural
models. Each line on the plot represents a
single protein chain.
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a fragment, where the second substitution (Gly278Asp)
occurs. Analyzing the differences in the main chain
trace with respect to wt prolidase structure, in both
cases one notes a two distinctive maxima of Ca devia-
tion from wt structure around residue 278 (primary
interaction or substitution) and around residue 240,
where polypeptide is pushed by displaced 277–279
fragments (Figs 2B and 3B). The destabilizing effect of
the substitutions is further seconded by an observed
decrease in the thermal stability of the variants, even
though the expression strain used had negligible effect
on the TM (Fig. 5A). Crystal structures are time and
space averages of all the molecules building a given
crystal and as such may not fully represent the local
heterogeneity of the sample. Ensemble refinement is an
approach utilizing molecular dynamic simulation
restrained by the experimental component derived
from the X-ray diffraction experiment and can be used
to estimate local structural heterogeneity. This method
has been employed to all of the discussed model, and
it was observed that the fragment encompassing two
strands, referenced to throughout the text, and a loop
connecting them (roughly residue range 235–281) exhi-
bit a slightly elevated flexibility in the wt prolidase
(Fig. S1C). In the case of all the variants, this flexibil-
ity is highly enhanced as indicated by RMSF values
calculated based on the phenix.ensemble_refinement. It
is of note that this enhancement is significantly smaller
in case of variants expressed in Arctic Express cells
(see panels D and E on Figs 2–4).
Fig. 3. Comparison of the Gly278Asp
variant of prolidase derived from two
different expression systems with the wt
prolidase structure. (A) Superposition of
mutant models (Prol_G278D_Ros—yellow,
Prol_G278D_ArEx—marine) with wt
human prolidase in light gray. Point of
substitution is highlighted in purple, and
substrate is shown in black. Discontinuity
in the model is approximated by a dashed
line (residues 242–243 and residues 257–
260 for Prol_G278D_Ros). (B) Differences
between Ca atoms (CaRMSD) based on
the superposition of the mutant model
with wt human prolidase. (C) Variability of
normalized B factors drawn for discussed
region in Prol_S202F models. (D, E) RMSF
of average residue coordinates and ADPs,
respectively, based on the ensemble
refinement. The coloring scheme is the
same as for the structural models. Each
line on the plot represents single protein
chain.
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Fig. 4. Comparison of the Gly448Arg
variant of prolidase derived from two
different expression systems with the wt
prolidase structure. (A) Superposition of
mutant models (Rosetta—yellow, Arctic
Express—marine) with wt (white) human
prolidase. Point of substitution is
highlighted in purple, and substrate is
shown in black. Discontinuity in the model
is approximated by a dashed line (residues
248–260 for both Prol_G448R_Ros and
Prol_G448R_ArEx). (B) Differences
between Ca atoms (CaRMSD) based on
the superposition of the mutant model
with wt human prolidase. (C) Variability of
normalized B factors drawn for the
discussed region in the Prol_G448R
models. (D, E) RMSF of average residue
coordinates and ADPs, respectively, based
on the ensemble refinement. The coloring
scheme is the same as for the structural
models. Each line on the plot represents
single protein chain.
Fig. 5. Relative prolidase stability and
activity. (A) Plot of TM of prolidase variants
measured by TSA. Numerical values are
reported in the table below. (B) The
relative enzymatic activity measured as
the amount of proline released from
GlyPro substrate upon reaction with
prolidase. Plot scaled to activity of wt
enzyme as 100%. Scale bars represent
½SD errors from at least three
independent measurements.
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In the case of the Ser202Phe variant, one can notice
a small rotational difference in the side chain position
between the Prol_S202F_Ros and Prol_S202F_ArEx
structures. This seems sufficient to allow a more wt-
like arrangement of the Prol_S202F_ArEx variant
(Fig. 2A). Additionally, decreased chain flexibility
(Fig. 2C) resulted in clearer maps and allowed tracing
of the entire model (Fig. S2). This, however, was not
sufficient to restore the enzymatic activity. Of note is
that for this variant not even residual activity was
reported in previous studies [52]. Since the enzymatic
assay used is based on end-point measurements, it can-
not be excluded with certainty that deterioration of
the enzymatic activity over the incubation time may
also have some influence on the measured activity
data. By performing the assay at a temperature, which
was significantly below the measured TM of the least
stable variant, however, we have tried to minimize this
potential effect.
An even bigger stabilizing effect was observed for
the Gly278Asp substitution, where in the ArEx model
no disordered fragments, characteristic for the Ros
model, were observed. Here, the biggest difference is
direction of the side chain of the introduced Asp278.
In the Prol_G278D_Ros model, it is directed toward a
neighboring strand where it hinders its proper folding.
In contrast, in the Prol_G278D_ArEx it is swung away
in the opposite direction where it introduces no disor-
der (Fig. 3A). In both models, the Arg237-Glu248 b-
strand exhibits a higher ADP, but the pattern is not
uniform (Figs 3C and S3). In the Prol_G278D_Ros
structure, a small increase in B normalized is observed
for the site of the substitution at the cost of large dis-
order in other chain fragments. In contrast, in
Prol_G278D_ArEx the b-strand exhibits less elevated
ADP at a cost of forcing the side chain of Asp into a
conformationally unfavorable position with a high B
factor (Fig. 3). Interestingly, despite retaining the
increased flexibility the Prol_G278D_ArEx preparation
has significantly higher enzymatic activity, reaching
8% of wt activity (Fig. 5). Of note is that in compar-
ison with Prol_S202F_ArEx, the Ca deviation around
Tyr241 is very small (Fig. 3B) and could highlight the
importance of this residue, which was previously iden-
tified as one of the residues stabilizing the architecture
of the active site [10].
Among the investigated prolidase variants, the
Gly448Arg variant bears the biggest difference in the
size of the side chain and causes the largest disorder of
the enzyme structure. In the case of the Gly448Arg
substitution, a structural disorder affects mainly a loop
region connecting two b-strands rather than b-sheet
itself and we could not identify any expression-related
differences in obtained models. We can speculate that
it is more likely to restore order in fragments with high
secondary structure propensity than in naturally more
flexible regions, such as loops. Interestingly, our activ-
ity assay indicates that Prol_G448R_ArEx exhibits
higher in vitro activity than Prol_G448_Ros. This is a
discrepancy that we cannot explain based on structural
investigation, and it shows that the effect of chaperons
may be even more elusive. This is in line with the
results of Besio et al. [17], who reported a stabilizing
effect of Hsp70/90 also on prolidase variants for which
no structural stabilization can be expected (Prol_231-
delY and Prol-E412K).
Conclusions
Prolidase deficiency is a rare recessive disorder caused
by LOF mutations in PEPD gene. Unfortunately, such
mutations are relatively little studied structurally. Sev-
eral therapies were tested, but to date no efficient
treatment for PD is available. Previously, it was
reported that the induction of Hsp70/90 in cultured
fibroblasts can partially restore the activity of a subset
of prolidase LOF variants. Here, we investigated the
effect of chaperone co-expression on a series of previ-
ously identified prolidase LOF related to structural
disorder. Our crystallographic studies prove that in
two of three analyzed prolidase variants prone to
structural disorder, the expression in the presence of
elevated concentration of chaperones significantly sta-
bilizes protein and reverts its native-like conformation.
We also show that enzymatic activity was partially
restored. Our results suggest that the induction of
chaperone activity may lead to stabilization and partial
recovery of enzymatic activity of LOF mutants and
therefore be considered as potential treatment. Both
Cpn10/Cpn60 used in this study and Hsp70/Hsp90
analyzed previously in human fibroblasts are broad-
spectrum chaperones, and therefore, we believe that
observed effects are generic rather than chaperone-spe-
cific. Our studies also show that an expression system
should certainly be considered as one of the variabili-
ties in structural analyses of proteins.
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Table S2. Per residue numerical values of CaRMSD
[A] of each variant vs wild type prolidase.
Fig. S1. (A) Structural aspects of human prolidase.
Fragment of human prolidase close to the dimer inter-
face is shown as sticks with composite omit map coun-
tered at 1.0 r. Monomer A is colored according to its
local B factor (blue: low B, red: high B) and monomer
B is colored following the chain trace to ease localiza-
tion of described mutants. The substrate and metal
ions are drawn with black ball-and-stick representation
to indicate location of the active sites. (B) variation of
B factors for both subunits for the discussed residue
range. The scale of the plot is kept constant to ease
comparison with later figures. (C) B-factor and coordi-
nate RMSF derived from ensemble refinement of the
wild-type prolidase are plotted for comparison with
panels D & E on Figures 2–4. Here the scale was
adjusted as using the same as for the mutants lines
plotted here would appear flat.
Fig. S2. Comparison of the Ser202Phe variant of proli-
dase derived from two different expression systems.
Fig. S3. Comparison of the Gly278Asp variant of prol-
idase derived from two different expression systems.
Fig. S4. Comparison of the Gly448Arg variant of prol-
idase derived from two different expression systems.
Fig. S5. Overlay of the full prolidase variant dimers on
the wild type prolidase drawn in the cartoon represen-
tation.
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